![]() |
Phase 1 results point to larger trial of enzalutamide and fulvestrant in breast cance
Results of a multicenter phase 1 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with...
More... |
| All times are GMT -7. The time now is 04:01 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021